Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis

A study protocol

Antoni Soriano-Arandes, MD, PhD, Joan A. Caylà, MD, PhD, Alessandra Queiroga Gonçalves, PhD, Ángels Orcau, MD, Antoni Noguera-Julian, MD, PhD, Emma Padilla, MD, PhD, Elisabet Solà-Segura, MD, Neus Rius Gordillo, MD, MSC, María Espiau, MD, PhD, Mónica G. García-Lerín, MD, María Àngels Rifa-Pujol, MD, Jordi Gómez i Prat, MD, MSc, Esperança Macia-Rieradevall, MD, MSC, Andrea Martin-Nalda, MD, Maria Enl-Rius, MD, José Santos Santiago, MD, MSC, Lídia Busquets-Poblet, MD, Raisa Morales Martínez, MD, Tomàs Maria Pérez-Porcuna, MD, PhD

Abstract

Introduction: Tuberculosis (TB) is a global infectious disease. In low-incidence countries, paediatric TB affects mostly immigrant children and children of immigrants. We hypothesize that these children are at risk of exposure to Mycobacterium tuberculosis when they travel to the country of origin of their parents to visit friends and relatives (VFR). In this study, we aim to estimate the incidence rate and risk factors associated to latent tuberculosis infection (LTBI) and TB in VFR children.

Methods and analysis: A prospective study will be carried out in collaboration with 21 primary health care centres (PCC) and 5 hospitals in Catalonia, Spain. The study participants are children under 15 years of age, either immigrant themselves or born to immigrant parents, who travel to countries with high incidence of TB (≥40 cases/100,000 inhabitants). A sample size of 492 children was calculated. Participants will be recruited before traveling, either during a visit to a travel clinic or to their PCC, where a questionnaire including sociodemographic, epidemiological and clinical data will be completed, and a tuberculin skin test (TST) will be performed and read after 48 to 72 hours; patients with a positive TST at baseline will be excluded. A visit will be scheduled eight to 10 days after returning home to perform the TST.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

This work was supported by a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2016 call under the Health Strategy Action 2013–2016, within the National Research Program oriented to Societal Challenges, within the Technical, Scientific and Innovation Research National Plan 2013–2016, with reference P16/00314, co-funded with European Union ERDF funds (European Regional Development Fund); by the Departament de Salut of the Generalitat de Catalunya, in the call for the year 2017 of granting grants of the Strategic Plan for Research and Innovation in Health (PERS) 2016–2020, modalitat Intensificació de Facultats Especialistes, with the file code SLT005/17/144; by the Spanish Society of Pneumology and Thoracic Surgery (grant number 90/2015). The funders will not have any authority over any of the activities of the project.

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Correspondence: Tomàs Maria Pérez-Porcuna, MD, PhD, Atenció Primària, Fundació Assistencial Mútua Terrassa, Terrassa, Spain (e-mail: tomas.perez.porcuna@gmail.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Soriano-Arandes A, Caylà JA, Gonçalves AQ, Orcau Á, Noguera-Julian A, Padilla E, Solà-Segura E, Gordillo NR, Espiau M, García-Lerín MG, Rifa-Pujol MA, Jordi Gómez i Prat, Macia-Rieradevall E, Martin-Nalda A, Enl-Rius M, Santos Santiago J, Busquets-Poblet L, Martinez RM, Pérez-Porcuna TM. Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis: a study protocol. Medicine 2020;99:36(e22015).

Received: 25 July 2020 / Accepted: 31 July 2020

http://dx.doi.org/10.1097/MD.0000000000022015
1. Introduction

It is estimated that one third of the world population is infected with *Mycobacterium tuberculosis* and that 5% to 10% of those infected will develop tuberculosis (TB) during their lifetime. Current global figures indicate that 10 million people develop TB every year, of which 1.1 million are children. Significantly, children infected with *M. tuberculosis* that do not develop the disease and that do not receive preventive treatment will constitute a reservoir of TB in the future. Consequently, the identification and administration of preventive treatment to children with latent tuberculosis infection (LTBI) are critical to the global TB control and eradication efforts.

In countries with low TB incidence, the burden of disease is notably higher in the immigrant than in the autochthonous population. Importantly, this higher incidence of tuberculosis persists beyond the first years after arrival to the host country. In fact, most new paediatric TB cases in western countries occur in immigrant children and autochthonous children born to immigrant parents.

In Europe, TB and hepatitis C are the main imported infections among the immigrant population. The recent increase in international travel of immigrants to their countries of origin to visit friends and relatives (VFR) and subsequent exposure to *M. tuberculosis* in countries with incidences of TB higher than in the host countries could partially explain the differences in incidence between children of immigrant families and children from the autochthonous population. It seems plausible to associate travel-related factors with risk of contagion, including the intensity of transmission (proportional to the local TB incidence), the relationship and contact with the local population, the duration of the stay, and individual host factors.

However, the risk of LTBI is difficult to estimate, firstly because of the lack of a gold standard for the diagnosis, and secondly due to the long incubation period before the development of the TB disease, specially in people over 5 years of age.

Due to the little evidence on the risk factors associated to LTBI and TB in VFR children, it is crucial to elucidate the epidemiology of TB in the immigrant population and their children to better inform public health policies aimed at reducing the number of TB cases.

The objectives of this study are (1) to estimate the incidence rate of LTBI and TB in paediatric VFR travellers when returning from the countries of origin of their parents and (2) to identify risk factors associated with LTBI and TB.

2. Methods and design

An interventional, single group assignment, multicentre study will be carried out from June 2017 to December 2020 in Catalonia. The incidence rate of LTBI/TB in Catalonia is 12.6 cases/100,000 inhabitants and 36.3 cases/100,000 inhabitants among the general and the immigrant population, respectively. BCG vaccination is not included in the national programme of immunization.

2.1. Setting and participants

Participants of the study are children that meet the inclusion criteria, attended at any of the 5 pre-travel health clinics or at any of the 21 primary health centres (PCC) involved in the study.

**2.1.1. Inclusion criteria (all criteria must be met).**

- Children less than 15 years of age, either immigrants or born in Spain to immigrant parents.
- Children with at least one of the parents from a high TB incidence country. We define “high TB incidence country” as a country with a TB incidence rate 3 times higher than in Catalonia, namely 40 cases/100,000 inhabitants or greater.
- Children with congenital heart disease.
- Children with cystic fibrosis and other congenital pulmonary diseases.

**2.1.2. Exclusion criteria.**

- Children with primary or secondary immunodeficiency due to treatment with corticosteroids, transplantation, treatment with anti-tumour necrosis factor, or chronic renal insufficiency.
- Children with congenital heart disease.

2.2. Sample size

The sample size was calculated using the GRANMO v7.2, 2012 program for the study of paired proportions, accepting an alpha
risk of 0.05 and a beta risk of 0.2 in a two-sided test. It was estimated that 492 subjects are necessary to obtain a statistically significant difference considering an initial LTBI proportion of 0% and a final proportion of 2%. A drop-out rate of 20% is anticipated.

2.3. Data collection

Baseline data collection: Eligible children will be offered to participate in the study during a programmed visit in a pre-travel health clinic or in a PCC. In the first visit, the parents or legal guardians will be interviewed to complete a questionnaire including socio-demographic, epidemiological, and clinical data. A tuberculin skin test (TST) will be performed and read 48 to 72 hours later. Figure 2 shows the study flowchart.

The TST will be made within 30 days prior to the trip. In BCG vaccinated children, TST will be performed and if the result is positive, a QuantiFERON-Plus® (QFT-Plus) test will be carried out to confirm the infection. Subsequently, if the QFT-Plus test is positive, the child will be excluded from the study and treated for LTBI.

Follow-up: A visit will be scheduled 8 to 12 weeks after returning from the trip. Here, a questionnaire with epidemiological and clinical data about the trip will be completed and a TST and QFT-Plus test will be simultaneously performed.

Children diagnosed with LTBI or TB, either at baseline or at follow-up, will receive treatment as per national guidelines, and relatives will be referred for contact tracing. Similarly, the investigators will verify the need for other preventive measures (malaria chemoprophylaxis, helminthiasis study, other immunizations, etc).

Data registration: The information collected in the questionnaires will be registered and managed in REDCap (Research Electronic Data Capture) tools hosted at Fundació de Docència i Recerca Mútua Terrassa. REDCap is a secure, web-based software platform designed to support data capture for research studies.[21,22]

2.4. Outcomes

2.4.1. Primary outcome. The primary outcome is the diagnosis of LTBI and/or TB after travelling to a high TB incidence country in accordance with World Health Organization (WHO) guidelines.[1] At the end of the study, patients will be classified as: “not infected; LTBI/TB disease; unknown/lost to follow-up”. Table 2 shows study variables and timing of data collection.

2.4.2. Secondary outcomes.

1. Sociodemographic data: sex, age, country of birth, country of birth of mother and father.
2. Clinical data: weight and height (before and after travel), BCG vaccination, presence of BCG scar.
3. Epidemiological data: pre-travel visit date, travel date, post-travel visit date, return date of the travel, trip duration, travel country, number of people that lived in host home, travel environment (rural / urban / mixed), smokers in host home, contact with a person suspected of having TB.

2.5. TST and QFT-Plus test procedures

Tuberculin Skin Test (TST): TST will be performed by intradermal injection of 2 UT of PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) and read after 48 to 72 hours. A positive test is defined as an induration greater than or equal to 10mm according to recommendations from the Agència de Salut Pública de Catalunya[23] and WHO guidelines.[1]

QuantiFERON-TB Plus (QFT-Plus) (Cellestis, Victoria, Australia; QIAGEN, Dusseldorf, Germany): We will draw four ml of blood per child and interpret the QFT-Plus test according to manufacturer’s instructions. Values ≥ 0.35 IU/ml in either TB1
Table 1
High and low tuberculosis incidence countries.

| Country/Territory                  | Estimated rate per 100,000 population | Number of cases |
|------------------------------------|---------------------------------------|-----------------|
| High tuberculosis incidence        |                                       |                 |
| Afghanistan                        | 189                                   | 70,000          |
| Algeria                            | 69                                    | 29,000          |
| Angola                             | 355                                   | 109,000         |
| Azerbaijan                         | 63                                    | 6300            |
| Bangladesh                         | 221                                   | 357,000         |
| Benin                              | 56                                    | 5600            |
| Bhutan                             | 149                                   | 1100            |
| Bolivia (Plurinational State of)   | 108                                   | 12,000          |
| Botswana                           | 275                                   | 6200            |
| Brazil                             | 45                                    | 95,000          |
| Brunei Darussalam                  | 68                                    | 290             |
| Burkina Faso                       | 48                                    | 9500            |
| Burundi                            | 111                                   | 12,000          |
| Cabo Verde                         | 46                                    | 250             |
| Cambodia                           | 302                                   | 49,000          |
| Cameroon                           | 186                                   | 47,000          |
| Central African Republic           | 540                                   | 25,000          |
| Chad                               | 142                                   | 22,000          |
| China                              | 61                                    | 866,000         |
| China, Hong Kong SAR               | 67                                    | 4900            |
| China, Macao SAR                   | 60                                    | 380             |
| Congo                              | 375                                   | 20,000          |
| Côte d’Ivoire                      | 142                                   | 36,000          |
| Democratic People’s Republic of Korea| 513                                 | 131,000         |
| Democratic Republic of the Congo  | 321                                   | 270,000         |
| Djibouti                           | 260                                   | 2300            |
| Dominican Republic                 | 45                                    | 4800            |
| Ecuador                            | 44                                    | 7400            |
| El Salvador                        | 70                                    | 4500            |
| Equatorial Guinea                  | 201                                   | 2600            |
| Eritrea                            | 89                                    | 3100            |
| Eswatini                           | 329                                   | 3700            |
| Ethiopia                           | 151                                   | 165,000         |
| Fiji                               | 54                                    | 480             |
| Gabon                              | 525                                   | 11,000          |
| Gambia                             | 174                                   | 4000            |
| Georgia                            | 80                                    | 3200            |
| Ghana                              | 148                                   | 44,000          |
| Greenland                          | 100                                   | 56              |
| Guam                               | 49                                    | 82              |
| Guinea                             | 176                                   | 22,000          |
| Guinea-Bissau                      | 361                                   | 6800            |
| Guyana                             | 83                                    | 640             |
| Haiti                              | 176                                   | 20,000          |
| India                              | 199                                   | 2,690,000       |
| Indonesia                          | 316                                   | 845,000         |
| Iraq                               | 42                                    | 16,000          |
| Kazakhstan                         | 68                                    | 12,000          |
| Kenya                              | 292                                   | 150,000         |
| Kiribati                           | 349                                   | 400             |
| Kyrgyzstan                         | 116                                   | 7300            |
| Lao People’s Democratic Republic   | 162                                   | 11,000          |
| Lesotho                            | 611                                   | 13,000          |
| Liberia                            | 308                                   | 15,000          |
| Libya                              | 40                                    | 2700            |
| Lithuania                          | 44                                    | 1200            |
| Madagascar                         | 233                                   | 61,000          |
| Malawi                             | 181                                   | 33,000          |
| Malaysia                           | 92                                    | 29,000          |
| Mali                               | 53                                    | 10,000          |
| Marshall Islands                   | 434                                   | 250             |
| Mauritania                         | 93                                    | 4100            |

(continued)

| Country/Territory                  | Estimated rate per 100,000 population | Number of cases |
|------------------------------------|---------------------------------------|-----------------|
| Micronesia (Federated States of)   | 108                                   | 120             |
| Mongolia                           | 428                                   | 14,000          |
| Morocco                            | 99                                    | 36,000          |
| Mozambique                         | 551                                   | 162,000         |
| Myanmar                            | 338                                   | 181,000         |
| Namibia                            | 524                                   | 13,000          |
| Nauru                              | 54                                    | 6              |
| Nepal                              | 151                                   | 42,000          |
| Nicaragua                          | 41                                    | 2600            |
| Niger                               | 87                                    | 19,000          |
| Nigeria                            | 219                                   | 429,000         |
| Niue                               | 71                                    | 1              |
| Northern Mariana Islands           | 95                                    | 54             |
| Pakistan                           | 265                                   | 562,000         |
| Palau                              | 109                                   | 20             |
| Panama                             | 52                                    | 2200            |
| Papua New Guinea                   | 432                                   | 37,000          |
| Paraguay                           | 43                                    | 3000            |
| Peru                               | 123                                   | 39,000          |
| Philippines                        | 554                                   | 591,000         |
| Republic of Korea                  | 66                                    | 34,000          |
| Republic of Moldova                | 86                                    | 3500            |
| Romania                            | 68                                    | 13,000          |
| Russian Federation                 | 54                                    | 79,000          |
| Rwanda                             | 59                                    | 7300            |
| Sao Tome and Principe              | 124                                   | 260             |
| Senegal                            | 118                                   | 19,000          |
| Sierra Leone                       | 298                                   | 23,000          |
| Singapore                          | 47                                    | 2700            |
| Solomon Islands                    | 74                                    | 480             |
| Somalia                            | 262                                   | 39,000          |
| South Africa                       | 520                                   | 301,000         |
| South Sudan                        | 146                                   | 16,000          |
| Sri Lanka                          | 64                                    | 14,000          |
| Sudan                              | 71                                    | 30,000          |
| Tajikistan                         | 84                                    | 7600            |
| Thailand                           | 153                                   | 106,000         |
| Timor-Leste                        | 498                                   | 6300            |
| Turkmenistan                       | 46                                    | 2700            |
| Tuvalu                             | 270                                   | 31              |
| Uganda                             | 200                                   | 86,000          |
| Ukraine                            | 80                                    | 36,000          |
| United Republic of Tanzania        | 253                                   | 142,000         |
| Uzbekistan                         | 70                                    | 23,000          |
| Vanuatu                            | 46                                    | 130             |
| Venezuela (Bolivarian Republic of) | 48                                    | 14,000          |
| Viet Nam                           | 182                                   | 174,000         |
| Yemen                              | 48                                    | 14,000          |
| Zambia                             | 346                                   | 60,000          |
| Zimbabwe                           | 210                                   | 30,000          |

Low tuberculosis incidence

| Country/Territory                  | Estimated rate per 100,000 population | Number of cases |
|------------------------------------|---------------------------------------|-----------------|
| Argentina                          | 27                                    | 12,000          |
| Belize                             | 30                                    | 110             |
| Colombia                           | 33                                    | 16,000          |
| Egypt                              | 12                                    | 12,000          |
| Guatemala                          | 26                                    | 4500            |
| Honduras                           | 37                                    | 3500            |
| Suriname                           | 38                                    | 220             |
| Togo                               | 36                                    | 2800            |
| Tunisia                            | 35                                    | 4000            |
| Turkey                             | 16                                    | 13,000          |

*estimated incidence rate of 40 per 100,000 population or greater.
†estimated incidence rate of less than 40 per 100,000 population. Source: World Health Organization (WHO) Tuberculosis burden estimates. https://www.who.int/tb/publications/global_report/en/.

(continued)
and/or TB2 antigen tubes will be considered positive. In the case of QFT-Plus values ≥0.2 and <0.35 (gray zone), the test will be repeated 4 to 8 weeks later. QFT-Plus can have a positive, negative or indeterminate result.

If TST and QFT-Plus results are discordant, the test with a negative result will be repeated 4 to 8 weeks later.

2.6. Statistical analysis

Qualitative variables will be described using frequency tables, and quantitative variables will be determined using median, mean and interquartile range (IQR). We will use paired proportions for comparisons. The incidence rate of LTBI and TB will be estimated per individual/month and person/year per country visited and by

| Study variables and timing of data collection. |
|-----------------------------------------------|
| **Characteristics**                          | **Type of response**                  | **Data collection** |
| **Sociodemographic data**                    | **Baseline**                          | **Follow-up**       |
| Sex; age                                      | Nominal; Quantitative (years)         | ■                    |
| Country of birth of the child                 | Nominal                               | ■                    |
| Mother’s country of origin                    | Nominal                               | ■                    |
| Father’s country of origin                    | Nominal                               | ■                    |
| **Clinical data**                             |                                          |                      |
| Weight; height                               | Quantitative (Kg); (cm)                | ■                    |
| BCG Vaccination                              | Nominal (Yes/No type)                 | ■                    |
| Presence of BCG scar                         | Nominal (Yes/No type)                 | ■                    |
| **Infection study**                           |                                          |                      |
| Tuberculin test date                         | Date (yyyy-mm-dd)                     | ■                    |
| Tuberculin test result                       | Quantitative (mm)                     | ■                    |
| QFT-Plus date                                | Date (yyyy-mm-dd)                     | ■                    |
| QFT-Plus result                              | Quantitative (UI/ml)                  | ■                    |
| Final diagnosis                              | Nominal                               | ■                    |
| **Epidemiological data**                     |                                          |                      |
| Date of visits                               | Date (yyyy-mm-dd)                     | ■                    |
| Age at visits                                | Quantitative (years)                  | ■                    |
| Travel country                               | Nominal                               | ■                    |
| Travel date (probablea/trueb)                | Date (yyyy-mm-dd)                     | ■ □                  |
| Return date of the travel (probablea/trueb)  | Date (yyyy-mm-dd)                     | ■ □                  |
| Time between tuberculin test and travel date (probablea/trueb) | Time in days | ■ □                  |
| Trip duration                                | Quantitative (days)                   | ■                    |
| Time between tuberculin test and return date | Time in days                          | ■                    |
| Number of people that lived in host home     | Quantitative (number of people)       | ■                    |
| Travel environment                           | Nominal (rural, urban, mixed)         | ■                    |
| Smokers in host home                         | Nominal (Yes/No type)                 | ■                    |
| Contact with a person suspected of having TB | Nominal (Yes/No type)                 | ■                    |

**Table 2**

BCG = Bacillus Calmette–Guérin vaccine, QFT-Plus = QuantiFERON-plus test, TB = tuberculosis.
age group. To identify factors associated with presence of LTBI or TB, the Fisher exact test or Chi-square test and the Mann-Whitney test will be used for bivariate analyses, followed by analysis of logistic regression calculating odds ratios and 95% confidence intervals. A 5% type I error will be estimated. Data will be exported from the REDCap database to PASW Statistics 25 (SPSS Inc., Chicago, IL) for statistical analyses.

2.7. Ethics
This study protocol (version 2, 01/02/2016) has been approved by the Clinical Research Ethics Committee of the Hospital Universitari Màtua Terrassa on 24/02/2016 (code 02/16) and by the Clinical Research Ethics Committee of the Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDiapJGol) on 25/04/2016 (code P16/094), in agreement with the Declaration of Helsinki/Tokyo. All parents or legal guardians of the participants will receive oral and written information about the study and Informed Consent will be obtained. Any amendment to the study protocol will be submitted to the ethical committees for approval.

The REDCap® database will be exclusively used by the team of researchers. The data included in the database used for statistical analyses will be anonymized and identified with internal codes of the project to avoid identification by the investigative team to guarantee confidentiality.

The results of the study will be published in scientific journals and will be presented in national and international meetings. The results will be communicated to participants in a meeting and via local and national media, and will also be disseminated to the general population.

3. Discussion
This study aims to evaluate the risk of LTBI and TB in paediatric VFR travellers that live in Catalonia, a low incidence TB region.[20] The study will be conducted in primary care centres, specialized travel clinics and hospital paediatric departments of the public health-care system. The joint role of primary care and infectious disease specialists is crucial in the implementation of strategies aimed at the eradication of TB in this population.[13] To our knowledge, this is the first study to prospectively analyse collected data from VFR children.

The few studies published with adults to date suggest that in non-VFR travellers, the risk of infection is similar to the local annual risk of TB infection.[24] In contrast, studies conducted with the immigrant population suggest that a significant percentage of TB cases are related to recent travel to the country of origin.[27] In the case of children, a population group with higher susceptibility to develop TB after primary infection, a case-control study from California reported an increased risk of LTBI in young paediatric VFR travellers and children of families that hosted visitors from countries with high TB incidence.[28]

Awareness of travel-associated risk of disease in VFR remains low, which might explain the scarce use of pre-travel health-care services by the immigrant population.[29] Moreover, the diversity of recommendations for different regions and countries demonstrates the limited information available on this topic.[30,31] Knowledge about the effectiveness of LTBI screening or BCG vaccination strategies also remains poor.[32] The implementation of strategies for the detection and treatment of LTBI cases should be prioritized to prevent new cases of TB in the paediatric and the adult population.[33]

Since state-level data are those usually published in official reports and regional incidence could vary significantly within the same country, a limitation of the study is the unavailability of data on regional incidence, which may hinder the assessment on the intensity of exposure to M. tuberculosis.[17] In addition, due to the specific immigration patterns of Catalonia, some countries of origin will be overrepresented in our sample.

The lack of gold standard for LTBI diagnosis responds to its paucibacillary nature, the quiescent state of M. tuberculosis and the localization in the mediastinal lymph nodes.[34] However, this is a universal limitation in all studies on this issue.

The low positive predictive value of the screening tests of LTBI in the general population constitutes another limitation. However, in low burden countries and among high risk groups such as immigrants and VFR travellers, tests may be useful for LTBI screening.[35]

Similarly, the TST and interferon-γ release assays have well described limitations, which can hinder the interpretation of results and the calculation of incidence rates, especially in the case of discordant results.[36,37] Again, this is a universal limitation in all studies on this issue.

The study will implement and evaluate a new detection strategy and management of LTBI in VFR children in a country with a low incidence of TB. This strategy may prove useful to design public health policies in regions with low incidence of TB with significant numbers of VFR travellers.

Acknowledgments
The authors thank the tuberculosis prevention and control program from the Agència de Salut Pública de Catalunya for study support.

Author contributions
Conceptualization: Antoni Soriano-Arandes, Joan A. Caylà, Àngels Orcau, Antoni Noguera-Julian, Tomàs María Pérez-Porcuna.

Data curation: Alessandra Queiroga Gonçalves, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, Maria Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lidia Busquets-Poblet, Raisa Morales Martínez.

Funding acquisition: Antoni Soriano-Arandes, Tomàs Maria Pérez-Porcuna.

Investigation: Alessandra Queiroga Gonçalves, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, Maria Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lidia Busquets-Poblet, Raisa Morales Martínez, Tomàs Maria Pérez-Porcuna.

Methodology: Joan A. Caylà, Alessandra Queiroga Gonçalves, Àngels Orcau, Antoni Noguera-Julian.

Project administration: Antoni Soriano-Arandes, Tomàs Maria Pérez-Porcuna.
References

[1] World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management; 2018. Available in: https://www.who.int/tb/publications/global_report/en/ [access date February 22, 2020].

[2] World Health Organization. Global tuberculosis report 2019; 2019. Available in: http://www.who.int/tb/publications/global_report/en/ [access date May 21, 2020].

[3] Vanden Driessche K, Persson A, Marais BJ, et al. Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013;2013:781320.

[4] Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:66-67.

[5] Thomas TA. Tuberculosis in Children. Pediatr Clin North Am 2017;64:893.

[6] Hoppe LE, Kettle R, Eisenhut M, et al. Tuberculosis diagnosis, management, prevention, and control: summary of updated NICE guidance. BMJ 2016;352:h657.

[7] Cruz AT, Starke JR, Lobato MN. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr 2014;26:106-113.

[8] Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2018. Demographics; 2019. Available in: https://www.cdc.gov/tb/statistics/reports/2018/demographics.htm [access date May 10, 2020].

[9] European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe, 2019; 2019. Available in: https://ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2019 [access date April 5, 2020].

[10] Boggild AK, Geduld J, Libman M, et al. Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet. J Travel Med 2019;26:3.

[11] Farah MG, Meyer HE, Selmer R, et al. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol 2005;34:1005-11.

[12] Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. JAMA 2008;300:405-12.

[13] Schlagenhoff P, Wendl L, Goorhuis A, et al. Travel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis 2015;15:55-64.

[14] Zuckerman JN. Recent developments: travel medicine. BMJ 2002; 325:260-4.

[15] Monge-Maillo B, Norman FF, Pérez-Molina JA, et al. Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants, or both? A comparative analysis. Travel Med Infect Dis 2014;12:88-94.

[16] Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. Travel Med Infect Dis 2011;9:192-203.

[17] Elfrink F, van den Hoek A, Mensen MF, et al. Screening travellers to high-endemic countries for infection with Mycobacterium tuberculosis using interferon gamma release assay; a prospective study. BMC Infect Dis 2014;14:515.

[18] Denholm JT, Thavaranan J. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. J Travel Med 2016;23:19008.

[19] Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon ( release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230-9.

[20] Agencia de Salut Pública de Catalunya. Departament de Salut. Informe anual 2017. Situación epidemiológica i tendència de l’endèmia tuberculous a Catalunya; 2019. Available in: https://ca.statistic.cat/tuberculosi/documents_profarxics/informe_anual_tuberculosis_2017.pdf [access date July 21, 2020].

[21] Harris PA, Taylor R, Thielke R, et al. Research electronic data capture ( REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.

[22] Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.

[23] Ángeles Riñó-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Naldà, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez. Writing – original draft: Antoni Soriano-Arantes, Joan A. Caylà, Àngels Orcau, Antoni Noguera-Julian, Tomàs María Pérez-Porcuana. Writing – review & editing: Àngels Orcau, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, Maria Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Naldà, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez.